Sign in
CompletedPhase 2

Safety, Tolerability and Preliminary Efficacy of Multiple Intra-articular Injections of LRX712 in Patients With Knee OA

Key facts

Who runs it
Novartis Pharmaceuticals
Where
Netherlands1 site in 1 countryChoose a country to see its sites
Status
Completed
Phase
Phase 2
People taking part
45 people enrolled
Started
20 Jul 2020
Ended
17 Jan 2025
Type of study
Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • LRX712
  • Placebo
Record updated
30 January 2026

Who can take part

Age
35 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Written informed consent must be obtained before any assessment is performed
  • To be eligible for inclusion in this study patients must meet all of the following criteria:
  • Patient must have a BMI between 18 -35 kg/m2
  • Patient must have symptomatic knee osteoarthritis predominantly in one knee (index knee)
  • Patient must have knee osteoarthritis (Kellgren-Lawrence grade 2 or 3) in the index knee, as confirmed by radiography
  • Patient must have radiographic confirmation of a medial joint space width of 1.5 to 3.5 mm for females, or 2 to 4 mm for males within the medial tibio-femoral compartment of the index knee

Who cannot take part

  • Previous use of LRX712 or use of other investigational drugs at the time of enrollment, or within 5 half-lives of enrollment, or within 30 days, whichever is longer; or longer if required by local regulations
  • Signs or symptoms, in the judgment of the investigator, of a clinically significant systemic viral, bacterial or fungal infection within 30 days prior to screening; Other protocol-defined inclusion/exclusion criteria may apply
  • Patient has a known autoimmune disease, inflammatory or chronic arthropathy other than OA
  • History of significant cardiac conduction/electrophysiological disorder, e.g. familial long QT syndrome or known family history of Torsades de Pointes or prolonged QT syndrome or QTcF ≥ 450 msec (Fridericia Correction) for males and ≥ 460 msec for females at screening or baseline (by local 12-lead digitized ECG reading)
  • Subjects meeting any of the following criteria are not eligible for inclusion in this study:
  • Patient had partial or complete joint replacement in one or both knees
  • Patient has symptomatic, isolated patello-femoral pain in the index knee as per the Investigator's examination
  • Pregnant or nursing (lactating) women
  • Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant
  • Patient has malalignment (valgus- or varus-deformity) ≥ 7.5° in the index knee as per anatomic PA axis measured by weight-bearing short knee radiography

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study explored the preliminary efficacy of multiple intra-articular injections of LRX712 by evaluating the ability of the drug to restore structural integrity of articular cartilage. Efficacy was evaluated in the context of the systemic safety and local tolerability of the investigational drug.

The 4 groups in the trial

  • LRX712 15 mgTreatment being tested

    LRX712 15 mg was administered intra-articularly (i.a.) every four weeks, for a total of three administrations.

    Treatment: LRX712

  • LRX712 25 mgTreatment being tested

    LRX712 25 mg was administered i.a. every four weeks, for a total of three administrations.

    Treatment: LRX712

  • LRX712 75 mgTreatment being tested

    LRX712 75 mg was administered i.a. every four weeks, for a total of three administrations.

    Treatment: LRX712

  • PlaceboPlacebo, for comparison

    Placebo was administered i.a. every four weeks, for a total of three administrations.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Placebo-controlled, Subject and Investigator Blinded Study Investigating the Safety, Tolerability and Preliminary Efficacy of 8-week Treatment With Intra-articular LRX712 to Regenerate Articular Cartilage in Patients With Mild/Moderate Knee Osteoarthritis
Record updated
30 January 2026